An ongoing clinical trial [1] evaluating the usefulness of anticoagulation therapy in patients with subsegmental pulmonary embolism (SSPE) and negative lower extremity ultrasound has newly stirred up the discussion regarding the clinical role of small peripheral pulmonary emboli ( Fig. 1 ) [2] .
Because radiology is deeply involved in this debate, we speculate that a short survey of this important matter should be of some interest to our readers.
In fact, as technology progresses, spiral computed tomography (CT) is now able to pick up very small pulmonary emboli, that radiologists could not see before. Consequently, over time, the frequency of detected pulmonary emboli has significantly increased.
The typical prevalence of the CT pulmonary angiography (CTPA) is 1 positive CT exam per 20 performed and the incidence of isolated SSPE is between 5%-15%, depending on the population investigated.
Until today, the treatment is substantially the same for large, central emboli and for small, peripheral SSPE. As a result, more and more people are now on blood thinners to treat very small emboli, whose clinical significance is still unknown. On the other hand, every year, 3% of treated patients develop a major bleeding event, requiring medical care (cerebral haemorrhage, gastrointestinal bleeding or bleeding following trauma).
An increasing number of investigators don't think that treating all these small emboli in the pulmonary arteries is worth the risk of bleeding due to treatment. In other words, the point is: are all pulmonary emboli created equal? Are all of them equally concerning? Which emboli need to be treated to prevent new episodes or death?
Once upon a time, in the era before anticoagulation, only
Uno studio clinico in corso [1] Fig. 1 ) [2] . Poiché la radiologia è profondamente coinvolta in questa discussione, riteniamo che una breve panoramica di questo importante argomento sia di grande interesse per i lettori.
sull'utilità della terapia anticoagulante nei pazienti con embolia polmonare subsegmentale (EPSS), ma senza segni di trombosi venosa all'ecografia degli arti inferiori, ha di recente riaperto il dibattito sul significato clinico dei piccoli emboli polmonari periferici (
Con il progredire della tecnologia infatti, la tomografia computerizzata (TC) spirale può ora evidenziare emboli polmonari molto piccoli, che i radiologi non hanno mai potuto osservare prima. Di conseguenza, negli ultimi anni, è notevolmente aumentata la frequenza di embolia polmonare rilevata nel corso di indagini diagnostiche.
La prevalenza di embolia polmonare (EP) nelle angio-TC polmonari (CTPA) è di un esame positivo ogni 20 eseguiti e l'incidenza di EPSS isolata è tra il 5% ed il 15%, a seconda della popolazione in esame.
Attualmente il trattamento dell'embolia polmonare è sostanzialmente lo stesso sia per i grandi emboli centrali sia per i piccoli EPSS periferici. Di [4] .
Numerosi studi radiologici, sia prospettici sia retrospettivi, hanno valutato la prevalenza di embolia polmonare non sospettata e rilevata incidentalmente in indagini TC di routine [5] [6] [7] . L'embolia come reperto incidentale è stata riscontrata nell'1,5%-3,4% dei casi, soprattutto nei soggetti di età oltre 60 anni, con una prevalenza ospedaliera dal 4% al 5% e prevalenza ambulatoriale dallo 0,6% al 2,2%.
In base all'esperienza di Farrell et al. [7] , il 30% di questi emboli trovati casualmente era localizzato nelle arterie subsegmentali. Dal 70% all'83% dei pazienti con embolia incidentale aveva il cancro. Tra i pazienti con cancro, circa il 10% ha avuto il riscontro TC di emboli clinicamente non sospettati. Il 30% di questi emboli non è stato segnalato al momento della prima valutazione radiologica [7] . In un altro studio retrospettivo, Gladish et al. [8] hanno trovato emboli polmonari incidentali nel 4% degli studi TC di pazienti oncologici, con una maggiore prevalenza tra pazienti con tumori ginecologici e con melanoma.
Anche la trombosi venosa profonda (TVP) asintomatica viene spesso riscontrata durante le stadiazioni oncologiche. Cronin et al. [9] , ad esempio, hanno osservato una incidenza del 3,3% di EP non sospettata ed hanno scoperto che la TVP incidentale era presente nell'8% dei pazienti sottoposti a stadiazione pelvica TC.
Nei pazienti con cancro, la presenza di EPSS di riscontro occasionale, non associata ad alcuna sintomatologia né a parametri clinico-laboratoristici specifici, come dimostrato da O'Connell et al. [10] , non ha alcuna influenza sulle condizioni cliniche né alcun impatto sulla sopravvivenza. In tutti i pazienti con EPSS che non avevano ricevuto alcuna terapia anticoagulante, l'EPSS appariva risolta al successivo controllo CTPA. Al contrario, embolie polmonari incimassive emboli were found intra vitam [3] and the disease was considered nearly always fatal, with a mortality estimate ranging from 30% to 80%.
The development of progressively more effective therapies and the introduction of modern imaging techniques (initially ventilation-perfusion scan, then spiral CT, that superseded scintigraphy as the most used imaging modality to assess for suspected pulmonary embolism about ten years ago) corresponded to a decrease in mortality rate to less than 3%, but the therapeutic success was probably overrated, because the treated emboli changed from those detected on the basis of clinical findings (large, central) to those detected using CTPA.
The above mentioned considerations recently induced Prasad et al. [2] to state that the story of pulmonary embolism is a story of overdiagnosis. Their view was famously anticipated by a classical paper by Robin in 1977 with the evocative title: "Overdiagnosis and overtreatment of pulmonary embolism: the emperor may have no clothes" [4] .
A number of radiological studies, both prospective and retrospective, assessed the prevalence of pulmonary embolism, previously unsuspected and incidentally detected on routine spiral CT exams [5] [6] [7] . Unsuspected embolism was found in 1.5%-3.4% of the cases, mainly in subjects over 60 years of age, with an inpatient prevalence of 4% to 5% and an outpatient prevalence of 0.6% to 2.2%.
In the experience of Farrell et al. [7] , 30% of these serendipitously discovered emboli were located in the subsegmental arteries. From 70% to 83% of the patients with unsuspected emboli had cancer. Among the patients with cancer, about 10% had CT unsuspected emboli, and 30% of these emboli were not reported at the time of initial reading [7] . In another retrospective study, Gladish et al. [8] found incidental pulmonary emboli in 4% of oncology patients undergoing CT, with a higher prevalence among patients with gynaecological malignancies and those with melanoma.
Asymptomatic deep venous thrombosis (DVT) has also been reported during cancer staging. Cronin et al. [9] , for example, reported a 3.3% incidence of unsuspected PE and found that incidental DVT was present in 8% of patients undergoing staging pelvic CT.
In cancer patients, the presence of unsuspected SSPE, not associated with any symptoms or clinical and laboratory specific parameters, as demonstrated by O'Connell et al. [10] , has no influence on clinical conditions nor any adverse impact on survival. In all patients with SSPE who did not receive any anticoagulant therapy, the SSPE seemed resolved by the next staging CTPA scan. On the contrary, unsuspected PE involving major vessels have poorer prognosis, with a long-term mortality rate similar to that of symptomatic PE patients [11] . There remains, however, the question of whether the SSPE represents an early manifestation of hypercoagulable state, which is associated with an increased dentali che coinvolgono rami maggiori hanno una prognosi peggiore, con una mortalità a lungo termine che si avvicina a quella dei pazienti con embolia sintomatica [11] . Resta comunque il dubbio se l'EPSS rappresenti una iniziale manifestazione di uno stato di ipercoagulabilità, associato ad un aumentato potenziale metastatico e protrombotico. Pertanto, nonostante le osservazioni di O'Connell et al. [10] , non vi è un'opinione condivisa sulla necessità di trattamento delle EPSS asintomatiche in pazienti con cancro [12] , benché in questi pazienti il rischio di sanguinamento maggiore secondario alla terapia anticoagulante possa essere superiore a quello di un'embolia polmonare.
Le EPSS sono piuttosto comuni anche nei pazienti non oncologici [13] e possono presentarsi isolatamente, in assenza di difetti di riempimento centrali o di maggiori dimensioni (probabilmente il 5% di tutte le EP rilevate [2] ).
Nel 1993 Gurney [14] [18] . Il tasso di mortalità è quindi rimasto pressoché lo stesso, mentre l'incidenza è raddoppiata.
Nel complesso, l'introduzione della CTPA è stata associata con una crescente incidenza di EP e solo una minima variazione della mortalità (peraltro non significativa).
Queste osservazioni sembrano dimostrare l'esistenza di una importante quota di sovradiagnosi (cioè riscontro di emboli clinicamente irrilevanti). Molti pazienti con una diagnosi di EP acuta potrebbero subire i rischi della terapia, senza trarre alcun beneficio [19] . Le [10] , there is no shared opinion on the need for treatment of asymptomatic SSPE in cancer patients [12] , even though in these patients the risk of bleeding due to anticoagulation may outweigh the risk of fatal pulmonary embolism.
SSPE are rather common even in non-cancer patients [13] and can occur in isolation, in the absence of central or larger filling defects (probably 5% of all detected PE [2] ).
In 1993 Gurney [14] asked: "if small emboli are missed at pulmonary angiography, what are the consequences for the patient?" and in 2005, Goodman [15] stated that: "it is not always clear whether small PE, in the absence of deep venous thrombosis, justify the expense, mortality and serious morbidity associated with anticoagulation".
The Fleischner Society [16] added that "the clinical relevance of small peripheral PE and the need to administer anticoagulants in such cases remain a subject of debate".
The clinical evidence was recently analysed by Wiener et al. [17] , on the basis of the evaluation of an American nationwide database. According to these authors, before the introduction of CTPA, the incidence of PE was stable at 62.1 per 100,000. The death rate decreased progressively during the last decade of the 20th century from 13.4 to 12.3 per 100,000. After the introduction of CTPA, the incidence of PE increased to 112.3 per 100,000 (81% increase) and the mortality slightly reduced to 11.9 per 100,000, but haemorrhagic complications due to blood thinners increased from 3.1 to 5.3 per 100,000 population (71% increase). Simultaneously, the diagnosis of small SSPE increased significantly [18] . The death rates remained nearly the same, whereas the incidence doubled. All in all, the introduction of CTPA L'EP acuta potrebbe essere in realtà un fenomeno sia sowas associated with a rising incidence of PE and a minimal change in mortality (not significant).
These observations seem to demonstrate the existence of a significant component of overdiagnosis (i.e., finding clinically unimportant emboli). A lot of patients with a diagnosis of acute PE may suffer the risks of therapy without any benefit [19] . Wiener et al.'s [17] conclusions, however, were very soon criticised.
Ashrani and Heit [20] pointed out that no direct evidence of overdiagnosis had been presented by Wiener et al. [17] nor any data showing that hemorrhagic events were directly related to anticoagulation. Moreover, the temporal sequence of events could not be determined from discharge diagnosis codes. For example, a person with discharge diagnosis codes for PE and intracranial haemorrhage could have been admitted with primary intracranial bleeding and developed a PE as a complication of the hospitalisation.
Nevertheless, evidence that overdiagnosis represents a real problem continued to increase.
In a retrospective review of their experience, Suh et al.
[21] reported on the prevalence of PE, lower extremity DVT and anticoagulation therapy of 50 patients, selected from 1273 consecutive CTPAs performed over a 6-month period. The authors clearly demonstrated that there is a wide spectrum of embolic disease ("dots" and "clots", in their words). Of the 50 patients with positive CTPA, 17 (34%) had "dots", i.e. small peripheral SSPE and a minimal clot burden, without any sign of DVT. The large majority of them (88%) received anticoagulation. The authors concluded that we need further studies to determine the significance of such "dots", considering the risk of anticoagulation, because the risk can outweigh the benefits.
Another problem not easy to resolve is the high CTPA interobserver variability for SSPE diagnosis with CTPA, which is greatly influenced by the level of experience of the radiologist [22] . Perrier et al. [23] in a study involving radiologists with different experience showed that 11% of CTPAs with an initial diagnosis of SSPE, re-interpreted by a highly experienced thoracic radiologist, were later proved negative. Therefore, many of the SSPE diagnosed with CTPA may be actually false positive results, due to a misinterpretation of the operator, to motion artefacts or to poor opacification of the vessel. In this regard, Carrier et al. [24] state that all CTPA scans positive for isolated SSPE should be reviewed by an experienced thoracic radiologist as a "second opinion".
Besides, not only the presence but also the number, size and position of the emboli and the whole clinical scenario should be taken into due consideration.
In some cases, isolated SSPE without DVT could be even considered a para-physiological, incidental finding, to be left alone.
Goodman [15] noted that a normal function of the pul- [29, 30] . monary capillary bed is to filter small clots to protect the systemic circulation. So, how do we determine which patients with small PE should be treated?
Tapson [25] suggested that examining the legs would likely be useful in these cases. A residual clot in the legs might identify the highest risk patients for recurrences. This author acknowledged that overdiagnosis of PE is a real phenomenon, but stated that it is likely that a subset of patients with incidental PE benefits from therapy.
Acute PE may well be both over-and underdiagnosed, because most patients who die from acute PE are still not suspected until death.
Sheh et al.
[26] evaluated retrospectively 2087 patients with pulmonary embolism. In their experience, from 2000 to 2007 the incidence of PE increased from 0.69 to 0.91 per 100 admissions, in strong correlation with increased use of CTPA. There was no change in mortality, but the casefatality rate decreased from 5.7% to 3.3%.
On average, emboli detected with CTPA were one half as lethal as those diagnosed with scintigraphy. The authors concluded that the shift in imaging from scintigraphy to CTPA resulted in increased diagnosis of a less fatal spectrum of emboli, raising the possibility of over diagnosis.
Of course, these conclusions don't take into consideration other important factors, such as the CT capability to offer an alternative diagnosis in patients with acute chest pain (e.g., aortic dissection), which clearly is not in the realm of scintigraphy. A retrospective study revealed that CTPA, performed for a clinical suspicion of acute PE, showed other clinically relevant findings, requiring immediate and specific intervention, in 27.5% of cases [27] .
The CT radiation exposure is progressively reduced but it is still higher than that of scintigraphy. A risk-benefit analysis was performed in a retrospective review of 1424 consecutive CTPA by Woo et al. [28] . Benefit-to-risk ratios were calculated by dividing the mortality benefit of preventing a fatal PE by the risk of radiation-induced cancer from the CT scan. The authors detected PE in 13.2% of patients. Both inpatients and emergency department patients had significantly higher rates of PE than outpatients (respectively 14% and 14.5% versus 6.8%). Males received significantly a higher dose than females (9.7 versus 8.4 mSv) but males had a significantly lower lifetime attributable risk of cancer mortality than females. Ambulatory women had the highest benefit-to-risk ratio. Of course, the benefit-to-risk ratio could be and probably will be decreased very soon by further optimising the radiation dose delivery, due to technology evolution. Woo et al. concluded that, depending on multiple factors such as patient demographics and radiation dose, the benefits of using CTPA for suspected PE range from 25 to 187 times the risks.
Besides, the risks of diagnosing and treating PE must be compared to the risks of missed diagnosis and non-treat- Under these conditions, patients diagnosed with isolated SSPE have favourable 3-month outcomes with a recurrence rate <1% and no PE-attributed deaths. D-dimer testing is also less sensitive for SSPE versus segmental or larger emboli (76% sensitivity versus 98%) [32] ; this implies that many symptomatic patients with a negative D-dimer result may actually be affected from isolated SSPE. These conclusions were confirmed in a review of 93 patients with isolated SSPE and no DVT, selected from 10.453 consecutive studies by Donato et al. [33] . Given that the combination of a negative D-dimer result and a non-high pre-test probability can, with reasonable safety, exclude a major PE without the use of CTPA, a greater use of these diagnostic algorithms is likely going to reduce the overdiagnosis of SSPE.
Considering the absence of prospective data demonstrating the benefits of treating SSPE and the risks associated with anticoagulant therapy, the results of the ongoing clinical trial [1] are expected in the scientific community to determine if and how patients with symptomatic SSPE should be treated.
Another potential future direction of research could be the proposal of a model of multiparametric "scoring" for symptomatic isolated SSPE based on the integration of the CTPA results with other clinical and laboratory parameters (D-dimer, Doppler lower limbs, PaO 2 , signs of right heart overload on echocardiography) in order to identify the categories of patients who can really benefit from a specific therapy.
In conclusion, the availability of modern CTPA obviously simplifies the diagnosis but it creates new, previously unknown problems. The need for further information is obvious, because multiple questions regarding acute PE and particularly isolated SSPE are still unanswered.
Single-photon emission computed tomography (SPECT), ventilation-perfusion scintigraphy and magnetic resonance (MR) may play a major role in the near future but the diagnosis of SSPE requires a very high spatial resolution and probably will remain a CT diagnosis.
Besides, based on Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II data (sensitivity 83%, specificity 96%) [34] , at a disease prevalence of approximately 5%, the number of false positive patients approaches the number of true positive CTPA studies for the detection of acute PE, and this problem is probably even Prasad et al. [2] at the end of their article, rightly stated that "PE captures all the complexity of medicine in the evidence-based era".
They argue (and we agree) that outcome-based clinical trials with long-term follow-up would be helpful to further guide management but "trial funding should move away from industry-sponsored studies, which continue to test triviality", alluding to the raging debate regarding the so called "disease mongering" [36] , one of the greatest problems of the modern medicine.
But that is another story. 
